Member Info for HereforHemo

Pingu a successful phase one would put the Hemogenyx Mcap, based on future revenues of $500m pa at $2bn+.

That's a lot of upside from the current $15m.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

"We are thrilled to take this critical step in advancing the development of HG-CT-1. This milestone not only validates our years of research and development, but also brings us closer to providing a transformative treatment for patients suffering from relapsed or refractory AML."

And providing shareholders great returns for their unyielding faith and support!

Already a few days in and with real time analysis the first human data is being collected.

Lookout very good imo.

Bodes well for Hemogenyx. Very impressive. https://ash.confex.com/ash/2024/webprogram/Paper206596.html

Assuming the first patient was treated at the back end of last week we should be getting an RNS on Monday to confirm it.

If we do hear on Monday then the clock is very much ticking as the most critical time for the patient is the first 28 days. Ideally we don't want to hear anything during this time and the longer it goes the more promising things will look for everyone.

So a confirmation RNS tomorrow will leave a more 19 or 20 trading days before we find out whether the science is every bit as good as we think it is.

Personally, although I recognise the risks, I'm extremely confident of a successful Phase 1 and the subsequent rerate of the SP. As to how high it could go I've no idea but you have to assume the Mcap would be many multiples of today's and should continue to increase as the trial progresses,additional patients come on board, Penn join the trial and the trial is expanded to pediatric AML and a subset of ALL.

Exciting times.

There are positives for investors to take BEFORE the trial even begins. Why would Vlad state when moving into their large purpose built laboratory that one of the reasons was "it gives them the ability to move into larger premises". Why would Hemogenyx build their own CAR-T manufacturing facilities complete with two clean rooms? Why would Penn (arguably the world leaders in CAR-T therapy) agree to collaborate with Hemogenyx and sign a Master Translational Research Agreement with them. Why would Penn and Anderson, the leading cancer centre in the US want to participate in the trials. Why would Prevail want to invest in Hemogenyx and pay nearly 300% above the current SP and why would kure.ai want to collaborate with Hemogenyx to develop a 24 hour manufacturing process for HEMO-CAR-T.

The answer is simple. They all think it will work.

I believe the vast majority of investors are underwater. It makes no sense they would sell upon positive news after waiting patiently for many years.

Just my take.

Micky although I expect a pretty rapid move up to £6 I certainly wouldn't be ecstatic. If and when we're up to the £15-20 range I might allow myself to get a little excited. Fair value imo.

Investors are focused on:

*inital results of HEMO-CAR-T AML trial from patient one.

*Penn joining the AML trial in the near future.

*the approval and commencement of the pediatric AML and a subset of ALL trial.

*CAR-T being granted Orphan Drug Designation status.

*24 hour CAR-T manufacturing.

Not to mention any update that's forthcoming on either CDX or CBR.

My take is initial positive results of CAR-T leads directly to a major either buying It and HEMO receiving royalty payments or entering into a JV.

Whichever way it goes, CAR-T is a multi billion dollar product candidate and any success will put the Hemogenyx's Mcap in that bracket. Personally that's exactly where I see them going.

#saving lives

#billionsandyears

I didn't, I was just being lazy. I thought it was insensitive to refer to the patient as 'it' so I can safely say I've got a 50% chance of being right.

Jackdaw I wish you a speedy recovery.

Mr I, I would agree, highly likely we'll hear about the first patient on Monday as I believe she received her injection this week.

The countdown to results starts now.

Clinical Trials Progress:

1. Expansion into Pediatric Indications:

Pediatric AML and ALL: The Company is seeking to expand the HEMO-CAR-T indication to include pediatric acute myeloid leukemia ("AML") and a subset of pediatric acute lymphoblastic leukemia ("ALL") patients. An amendment to the clinical protocol to include pediatric AML is currently under review by third party experts. If approved, the Company will seek to implement the clinical trials for pediatric AML at the newly established clinical site. This area is of particular concern, and there is an urgent need for effective treatments for these conditions, which the Company believes HEMO-CAR-T will be able to provide.

2. Chimeric Bait Receptor ("CBR") Platform

The Company's CBR platform is an advanced immunotherapy designed to reprogram or redirect innate immune cells, such as macrophages, to prevent and combat infections from both existing and emerging viral threats, as well as to eliminate specific types of cancer.

Development and Testing:

· CBR Constructs: Scientists at Hemogenyx Pharmaceuticals are developing and testing multiple CBR constructs to identify the best candidates for targeting rare cancers such as epithelial ovarian carcinoma. Selected candidates will undergo rigorous testing to advance them to investigational new drug (IND) enabling studies.

mRNA-Based Delivery of CBR:

· Intranasal Delivery for Viral Infections: The Company continues to develop mRNA-based delivery of CBRs for treating airborne viral infections via intranasal administration. Recent improvements in the stability of mRNA-based CBRs are expected to enhance the effectiveness of this treatment.

3. CDX - Bispecific Antibody

IND-Enabling Studies:

· Progress: The Company is advancing IND-enabling studies for CDX, a bispecific antibody designed for treating relapsed and/or refractory AML, a subset of ALL, and for conditioning in bone marrow transplants.

Dr. David Wald, Founder of Kure.ai and Professor at Case Western Reserve University, added:"We are excited to partner with Hemogenyx Pharmaceuticals to adapt our ultrafast manufacturing platform to their innovative CAR-T therapy. This collaboration not only advances next-generation CAR-T solutions but also demonstrates the real-world clinical utility of our technology in addressing urgent unmet medical needs."

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukaemia and a subset of acute lymphoblastic leukaemia in children. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the Company to a significant value inflection point through the completion of its planned clinical trial."

Ghord the exciting thing about the funding is not that it covers the first injection, its the fact that it covers the results, and in all probability the second injection.

For investors and gamblers alike, people holding on good news could and should lead to a massive rerate which in turn would lead to any subsequent raise less dilutive and far more bearable.

Jackdaw wise words, obviously you make money everywhere. Just a shame your intellect doesn't stretch as far as your money. Heres your recent HEMO post:

Just Dumped19 Feb 2025 11:37

I just sold 800 at a lost, swapped over to IQAI

HOPEFULLY to get back what I lost here. I added earlier, I'm out fed up with this kaka

But you keep buying low and selling high. Even a monkey can do it.

It would be fantastic if Hemogenyx are awarded this. Multiple benefits including grants and tax credits.

https://www.ajmc.com/view/unlocking-the-benefits-of-fda-s-orphan-drug-designation

The bottom line with this funding is no inside shorters from Peterhouse, just loyal investors so the SP went UP not down.

I believe the next upward movement will be the first injection RNS and ny calculations are thats due tomorrow or Monday.

Don't forget we could get Orphan Drug status awarded anytime, potentially putting millions of pounds into the trials budget. Theres lots of positives as to why im confident but none more so than us having worked with Penn, who will join the trial in the future. https://hemogenyx.com/announcements/car-t-agreement-with-university-of-pennsylvania/

Imagine a research and development company who took a product candidate through IND enabling studies, were granted FDA approval to commence clinical trials, became a Clinical company, had Prevail invest at hundreds of percent above the current SP, recently raised approximately $600k to fund the initial patients in Phase one of the clinical trial and were starting the said trial like NOW, and being able to invest in them at a price the same as before any of the above even happened.

Personally I think that's a great opportunity.